Emerging Markets Report: The Tipping Point
One World Pharma Inc. (OTCQB: OWPC) is transitioning into its first revenue phase, a significant milestone for the Colombian cannabis producer. Led by Isiah Thomas, the company has navigated licensing, infrastructure, and agricultural challenges, positioning itself for revenue generation through its Futures program. Recent investor presentations have underlined the importance of transparency and strategic planning in this endeavor. As the company prepares to harvest and sell, it aims to leverage Colombia's favorable climate for cannabis growth.
- Entering a transformative first revenue phase.
- Navigated complex logistical challenges in licensing and infrastructure.
- Strong leadership from Isiah Thomas with a background in business.
- Establishing a compelling Futures program for large customer solicitation.
- None.
An Emerging Markets News Commentary
ORLANDO, Fla., Oct. 07, 2020 (GLOBE NEWSWIRE) -- As regular readers of the Emerging Markets Report know we’re big fans of two things at the small cap level:
Transparency and Revenue.
And while we argue in-house about which matters more, the reality is no real deal can exist in perpetuity without both being in place. And that’s why we’re now most pleased with some recent developments by Isiah Thomas’s Colombian cannabis producer, One World Pharma Inc. (OTCQB: OWPC).
A short while ago, Thomas and team held a zoom Investor Presentation where they covered a myriad of items and took questions from investors. We highly encourage investors to take an opportunity to hear this first-person update on some really important developments for OWP.
It’s clear they are at a tipping point.
Here’s a link:
We appreciate Thomas’s transparency and proactivity. It’s more than clear that the legendary athlete is bringing a stellar business background to this cannabis play, most notably his success with Cheurlin Champagnes where a deep relationship with the soil and sun, the people and the plant are also required. Thomas’s hoops background aside, he appears to be very well prepared to lead OWP into what they are calling their ‘first revenue phase.’
It’s not going unnoticed. Check out a recent Benzinga feature about Isiah’s path to One World Pharma.
But it’s the ‘entering its first revenue phase’ statement that is what we’re really focused on with OWP. It could truly be transformative.
There are myriad cannabis plays in public markets. Very few are established in Colombia where Mr. Thomas often extols the “equatorial advantage” in the favorable climate for growing hemp and cannabis at scale.
Entering a revenue phase also means that the Company has climbed the logistical mountain of licensing, infrastructure, labor, and seed characterization. A gargantuan task no less.
As Isiah explains in the presentation, now comes an opportunity to harvest and sell, to solicit very large customers and grow to spec via its compelling Futures program and to at-last reap the harvest of revenue… from the harvest.
So we will continue to follow One World Pharma armed with more clarity about the opportunity, and as the Company at last pursues ever-important revenue from long anticipated harvests.
For more information on One World Pharma please visit:
About One World Pharma
Formed in 2017, One World Pharma Inc. (“OWP”) is a fully licensed global supplier of high-quality hemp and cannabis derived ingredients for use in the manufacturing of Medical, Pharmaceutical, Consumer Packaged Goods (CPGs) and Over-the-Counter (OTC) products. OWP offers a reliable and sustainable supply chain for formulators, food & beverage producers as well as beauty product manufacturers worldwide. The company maintains corporate offices in Las Vegas, NV and Bogota Colombia and a facility in Popayan, Colombia.
About The Emerging Markets Report:
The Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stockbrokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.
For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.
DISCLAIMER:
EMC has been paid 145,000 dollars and 425,000 restricted shares by One World Pharma. EMC has a contract to receive 40,000 dollars over the next six months.
KP Investment partners invested 50,000 dollars in One World Pharma. EMC acquired a unit that translates into shares at .20 and a warrant. CEO of Emerging Markets James Painter has a
Additionally, Integrity Media holds 780,000 shares and receives
http://emergingmarketsllc.com/disclaimer.php
Must Read OTC Markets/SEC policy on stock promotion and investor protection
- https://www.otcmarkets.com/learn/policy-on-stock-promotion
- https://www.otcmarkets.com/learn/investor-protection
- https://www.sec.gov/news/press-release/2017-79
- https://www.sec.gov/oiea/investor-alerts-bulletins/ia_promotions.html
Emerging Markets Consulting, LLC
Florida Office
15701 State Road 50, Suite #205
Clermont, FL 34711
E-mail: jamespainter@emergingmarketsllc.com
Web: www.emergingmarketsllc.com
FAQ
What is the recent development regarding One World Pharma (OWPC)?
Who leads One World Pharma?
What challenges did One World Pharma overcome?
How does Colombia benefit One World Pharma's operations?
What is the Futures program mentioned in the press release?
